NCT04897009View on ClinicalTrials.gov

Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

June 8, 2026

Study Completion Date

June 8, 2026

Conditions
Invasive Breast Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and tissue collection

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT04897009 - Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer | Biotech Hunter | Biotech Hunter